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Introduction 
The autonomic system and sympathetic activation appears integral in the pathogenesis of 
acute mountain sickness (AMS) at high altitude (HA), yet a link between heart rate variability 
(HRV) and AMS has not been convincingly shown. In this study we investigated the utility of 
the smartphone-derived HRV score to predict and diagnose AMS at HA.  
Methods  
Twenty one healthy adults were investigated at baseline at 1400m and over 10 days during a 
trek to 5140m. HRV was recorded using the ithleteTM HRV device.   
 Results 
 AMS occurred in 11 subjects (52.4%) at >2650m. HRV inversely correlated with 
AMS Scores (r=-0.26; 95% CI -0.38 to -0.13: p<0.001).  HRV significantly fell at 3700m, 
4100m and 5140m versus low altitude.  HRV scores were lower in those with both mild 
(69.7±14.0) and severe AMS (67.1±13.1) versus those without AMS (77.5±13.1; effect size 
n2=0.043: p=0.007).  The HRV score was weakly predictive of severe AMS (AUC 0.74; 95% 
CI 0.58 to 0.89: p=0.006). The change (delta) in the HRV Score (compared with baseline at 
1400m) was a moderate diagnostic marker of severe AMS (AUC 0.80; 95% CI 0.70 to 0.90; 
p=0.0004). A fall in the HRV score of >5 had a sensitivity of 83% and specificity of 60% to 
identify severe AMS (likelihood ratio 1.9). Baseline HRV at 1400m was not predictive of 
either AMS at higher altitudes. 
Conclusions 
The ithlete HRV score can be used to help in the identification of severe AMS, however a 
baseline score is not predictive of future AMS development at HA  
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INTRODUCTION 
High altitude (HA) illness consists of Acute Mountain Sickness (AMS), which is usually a 
self- limiting collection of symptoms including headache and lethargy, which can lead to? 
HA Cerebral Edema (HACE) and HA Pulmonary Edema (HAPE).  HACE and HAPE are 
life-threatening.1The incidence of AMS is dependent on a number of factors which include 
individual susceptibility, the speed of ascent and altitude attained.2 It is known to affect 
>50% of persons at ascending to an altitude of 5000m.1-4  
The mechanism of AMS development is highly complex and is still not fully 
understood.1 HA-related hypoxia and changing homeostasis triggers a number of well-
established physiological responses which include the adrenal medullary release of 
epinephrine and an increase in whole body and tissue specific sympathetic nerve activity.5 
This leads to an increase in metabolic, heart and respiratory rate and changes in cerebral 
blood flow, that act to counteract the effects of hypobaric hypoxia.5-7 There is accumulating 
evidence to suggest that the autonomic system and alterations in the 
sympathetic/parasympathetic balance may play an important pathogenic role in the 
development of AMS and its susceptibility.7-11   
 Heart rate variability (HRV) represents an increasingly utilised, yet non- invasive 
method of assessing autonomic function. HRV is quantified by measuring changes in cardiac 
beat-to-beat (R-R) intervals which are under continuous autonomic control.12  Conditions that 
are known to affect the sympathetic/parasympathetic balance such as inter-current illness, 
cardiovascular disease, physical overtraining ande mental stress have been shown to lead to a 
reduction in HRV.13-15  Changes in HRV have been demonstrated on ascent to HA and 
typified by an increase in measures of sympathetic and a decrease in parasympathetic 
activity.16,17 However, a link between alterations in HRV and AMS development at HA has 
not been convincingly shown.3,18-21    
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Traditional methods of HRV measurement have required relatively large and 
expensive equipment with a need for at least five minutes of electrocardiographic (ECG) 
recording.22 The ithelte™ (HRV Fit Ltd, Southampton, UK) system is a recently available 
method of non-invasive HRV assessment from only 55 seconds  of recording obtained via a 
chest strap or finger sensor linked to a mobile smartphone. The ithelte™ generates an 
intuitive 1-100 HRV score which is a logarithmic adaptation of the root mean square of 
successive R-R intervals (RMSSD) provided by traditional HRV devices.23 It has ben shown 
that the RMSDD, can be derived from shorter recording times and is less prone to the effects 
of respiration, which is advantgeous for the HA environment where hypoxia and 
hyperventilation is typical.24-26 The ithlete HRV score has been shown to provide good to 
excellent agreement with the RMSSD obtained from a standard five minute 
electrocardiographic recording at sea level and more recently at HA.25,27  
The aim of this study was to investigate, for the first time, the practical use of the 
ithelte™ HRV monitor as a way of monitoring acclimatisation to HA and the onset of AMS. 
 
METHODS 
Subjects 
Healthy British Military service personnel aged >18years were included. Health status was 
confirmed following a detailed baseline health questionnaire. All subjects had to be in date 
with their fitness assessments including the military fitness standard for a 1.5 mile run. Key 
exclusion criteria included subjects with any history of cardiac arrhythmias or need for either 
rate or rhythm controlling medications. All subjects lived at low altitude and none had prior 
exposure to >1400m terrestrial altitude in the four weeks prior to this study.  
Data collection took place during a trek to Dhaulagiri base camp (western Nepal).  
Subjects were all part of the British Services Dhaulagiri Medical Research Expedition.  After 
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arriving at Kathmandu at 1400m, the subjects travelled by road to 890m, then 2650m before 
commencing the ascent on foot to 5140m (over Dhamphus Pass, 5240m) over 10 days (figure 
1). 
 
Recording of Heart Rate variability (HRV) 
HRV was recorded at approximately 0700 each morning using a finger sensor and linked 
smartphone via the ithlete™ app (HRV Fit Ltd. Southampton, UK) as previously described 
and validated.25,27 All participants were studied post micturition but prior to breakfast or 
caffeine. All subjects were seated, wearing warm clothing in either a tent or building. All 
subjects were encouraged to rest for at least five minutes before the HRV recordings were 
obtained.  The ithelte™ acquires a 55 second recording with visual breathing prompts to 
regulate the rate of both inspiration and expiration in order to standardise the HRV 
measurements. The ithlete™ modifies the acquired RMSSD by taking the natural log 
transformation and multiplying by twenty (lnRMSSD × 20) to provide a more interpretable 
HRV score for the user on a ∼100 point scale.23 It has a patented algorithm for the exclusion 
of both artifacts and ectopic beats whereby R-R (P-P) intervals of <500ms or >2000ms are 
excluded as are abnormal adjacent R-R intervals whose difference significantly exceeds the 
mean R-R interval.28 
 
 
Acute mountain sickness (AMS) scores  
Measurement of AMS was undertaken at the same time that HRV assessments were 
performed using the Lake Louis Scoring System (LLS).29,30 A total score of >3 in the 
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presence of headache was used to diagnose AMS and a score >5was considered consistent 
with severe AMS.29-31  
 
Physiological measurements 
Oxygen saturations (SpO2) and heart rate were measured using a Nonin Onyx (Nonin 
Medical Inc, Plymouth, Minnesota) pulse oximeter just prior to the assessment of HRV.  
 
Ethics 
The study was approved by the Ministry of Defence Research Ethics Committee and 
complied with the standards set in the Declaration of Helsinki.  All subjects gave written 
informed consent. 
 
Statistical analysis 
Statistical calculations and figures were performed using GraphPad Instat and GraphPad 
Prism version 4.00 for Windows.  Normality of continuous data was assessed following 
inspection and the Kolmogorov-Smirnov statistic.  All continuous data are presented as the 
mean ± standard deviation. Independent two group comparisons of continuous data were 
analysed using an unpaired t test or Man Whitney test for parametric and non-parametric data 
respectively. Comparisons of continuous data from >3 groups of parametric and on 
parametric data were performed using a one-way ANOVA or Kruskal-Wallis test 
respectively. The effect size (n) for any potential changes in HRV with HA was also 
calculated as the sum of squares for between-treatment effects divided by the total sum of 
squares. Correlation analyses were performed using Pearson Correlation and Spearman’s 
rank correlation with 95% confidence intervals depending on data normality. Receiver 
operating characteristic (ROC) curves were constructed to assess the sensitivity and 
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specificity of the ithlete™ and the area under the curve (AUC) for the HRV score to 
accurately identify subjects with AMS was determined. A p value of <0.05 was considered 
significant for all comparisons.  
 
RESULTS 
Twenty one subjects (20 men, 1 woman) aged 36.2±6.9 (years were studied over their 
first 13 days in Nepal (table 1).    Seventeen subjects reached 5140m on day 11, two on day 
13 and two beyond the study period.  There was a significant fall in SpO2 and increase in 
resting heart rate with gains in HA (Table 2). There was also an overall increase in LLS at 
HA (table 2) compared with the values at 890m. Successful ithleteTM recordings were 
possible in 93% of cases. AMS occurred in 11 subjects (52.4%) and all at an altitude of 
>2650m. There was a weak but significant correlation between HRV score and SpO2 r=0.16; 
95% CI 0.02 – 0.29: p=0.02). HRV inversely correlated with LLS Scores (r=-0.26; -0.38 to -
0.13: p<0.001). There was a moderate inverse correlation between the HRV score and heart 
rate (r=-0.41; -0.52 to 0.30: p<0.0001). 
 
HRV and acute Mountain Sickness 
There was a non-significant trend to reducing HRV score with increasing HA (n2 0.042; 
p=0.09) (table 2 and figure 2). However, this fall was significant at 3700m, 4100m and 
5140m versus 890m. The HRV score fell with increasing AMS Scores (ANOVA n2=0.043; 
p=0.007) (figure 3), but this difference was only significant on post-test between those with a 
LLS of 0 versus those with a LLS >5. HRV scores were significantly lower in those with 
AMS (mild and severe combined) 67.9±13.1 vs those without AMS 77.5±13.1 (p=0.002). 
HRV scores significantly fell from 77.5±13.1 for those with no AMS to 69.7±14.0 with mild 
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 8 
AMS and 67.1±13.1 with severe AMS (p=0.007, figure 4), however the difference was only 
significant between those without AMS and those with severe (not mild) AMS on post-test.   
The HRV score was very marginally better at distinguishing severe AMS versus those 
without severe AMS (ROC curve 0.74; 95% CI 0.58 to 0.89: p=0.006) than differentiating all 
AMS (mild and severe combined) from no AMS (area under the curve [AUC] 0.71: 95% CI 
0.58 to 0.84; p=0.002) (figure 5). An HRV score of <76 had a sensitivity of 83% and a 
specificity of 53% for the correct identification of severe AMS at a likelihood ration of 1.80 
(figure 5). However, the change (delta) in the ithlete™ HRV Score (compared with baseline 
at 1400m) was a better predictor of severe AMS (AUC 0.80; 95% CI 0.70 to 0.90; p=0.0004) 
(figure 6). A fall in the HRV score of >6 points compared had a sensitivity of 83% and 
specificity of 60% to identify severe AMS (likelihood ration 1.9) (figure 6). There was no 
difference in the HRV scores at 1400m between those who did or did not develop severe or 
any AMS at higher altitudes. 
 
DISCUSSION 
This is the first study, to the author’s knowledge, to investigate the link between AMS and 
HRV at HA to 5140m using a portable smart phone HRV device (ithleteTM). The ithleteTM 
HRV Score inversely correlated with the LLS but was a relatively weak discriminator for the 
identification of AMS and its severity. However, a fall in the HRV score, at HA versus 
baseline, of >6 versus baseline was a moderate albeit non-specific marker of severe AMS.  
 There is an increasing body of research that has shown that HA exposure leads to a 
reduction in HRV. This is thought to relate to a significant increase in sympathetic and a 
decrease in parasympathetic tone.17,18,22  With acclimatization there appears to be progressive 
shift toward a higher parasympathetic tone.31  Much less is known about the link between 
HRV and AMS. There is data to suggest that changes in HRV are linked to the AMS 
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susceptibility and development.19,22  but also data to the contrary challenging refuting this the 
link.20,21 This conflicting data may be partly explained by the marked differences in the 
design, ascent profile and the methods of HRV recording across the studies. Karinen et al 
studied 36 climbers on four different expeditions and three differing ascents.  The authors 
found that those with a lower HRV (RMSSD2min and HF [high frequency] 2min from a five 
minute HRV recording) at 2400m predicted those who later developed AMS at moderate 
altitudes (3000-4300m).22  Huang et al study 32 patients over a progressive HA trek to 
3440m. They noted that those with both (high frequency) HF% < 20% (suggesting reduced 
parasympathetic tone) and low frequency: high frequency (LF:HF) ratio > 1.3 (increased 
sympathetic balance) measured at 1317 m had an odds ratios of 7.00 (p = 0.047) for the 
subsequent development of develop AMS at 3440m (Huang 2013).19 The authors did not 
report data on the RMSSD.  In our study whilst we did observe significantly lower ithleteTM 
HRV (RMSSD) scores in those with AMS and more severe AMS, lower altitude HRV scores 
failed to predict AMS development at HA.  Furthermore the effect size for change in HRV 
with worsening AMS severity was modest.  
   
 One of the major additional confounders in all of these studies examining the 
relationship of HRV to symptom of AMS has been in the definition of AMS itself. The 
diagnosis of AMS is made using a self-reported questionnaire based assessment, most 
notably the LLS and is highly subjective and therefore likely to be influenced by a subjects’ 
expectations or aspirations and it can be a relatively poor predictor of illness.33,34 For 
example, in a previous study of 248 healthy adults travelling to 3200m Bartsch has noted that 
only 61% of the mountaineers reporting a LLS>5 actually said they felt ill.35 Hence, a more 
reproducible and objective measure of HA- related illness would be welcome.  The rational 
for using HRV to improve the detection of AMS is strong. Whilst the underlying 
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pathophysiology of AMS is still poorly understood current evidence suggests that it involves 
vasogenic cerebral oedema secondary to hypoxia-induced sympathetic activation.1 The 
normal physiological diuresis at HA, which acts to reduce plasma volume and increase in 
haematocrit (to improve tissue oxygenation) , is also affected leading to a reduced water 
clearance and a positive net water balance.36  Changes in plasma volume which is integral to 
the HA acclimatisation and AMS development are strongly influenced by alterations in 
parasympathetic tone.37  HRV is also heavily afeected by a number of other autonomic 
stressors such as fitness levels, physical fatigue, cold and exertion which important factors at 
HA and are known to be  contributory factors to AMS development and progression.38 
One of the greatest clinical applications of the ithleteTM and other HRV measures is in 
the detection of overtraining which shares many features in common with AMS.  Hence 
further studies examining the utility of HRV to monitor recovery from exercise at HA and to 
tailor individuals’ acclimatisation, rather than relying on guidelines such as 300m ascent per 
day, would be welcome.  The ithleteTM is currently marketed with a visual display of other 
domains such as sleep, fatigue, irritability and muscle soreness which could be potentially 
adapted to give a scale related to the LLS and is an area worthy of further research. 
 
This study has a number of limitations and strengths that need to be acknowledged. 
The ambient temperature varied throughout the study and the HRV measurements were 
performed in tents above 1400m. It is well known that change in both environment and 
temperature can influence HRV and due to the nature of this study it was not possible to 
adjust for these factors.38 In this study we used a finger probe rather than a blue tooth chest 
strap sensor to acquire heart beat data and successful data recording was not possible in 7% 
which could have influenced the findings. The ithleteTM only provides a single measure of 
HRV from a very short recording time. Hence, we do not know whether our findings would 
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be different if another HRV platform and a five-minute recording period with a wider array 
of HRV data outputs include frequency domain analyses were used. The ithleteTM HRV score 
is related the RMSSD and is considered a marker of relative parasympathetic activity and 
does not assess sympathetic tone or the sympathetic/parasympathetic balance provided by 
more sophisticated devices. However, the aim of this study was to assess the utility of a 
simple, inexpensive, portable and user friendly deice that is widely available to potentially 
predict HA related illness and hence maximising the clinical impact of a potentially strongly 
positive finding. The key strengths of this study was that all subjects underwent the same 
exercise, diet and acclimatisation protocol and the altitude achieved was significant and 
greater than the majority of published HRV studies at HA.  
In summary this is the first paper to show a practical application of a simple measure of 
HRV to provide an objective measure of severe AMS.  A fall in the ithleteTM HRV score of 
>6 points from baseline had moderate precision for the detection of severe AMS.  
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Legends for Figures 
Figure 1 Ascent profile  
Figure 2 Changes in ithleteTM Heart Rate Variability Score with increases in altitude  
Figure 3 Changes in Heart Rate Variability with Acute Mountain Sickness Scores (LLS) 
Figure 4 Acute Mountain Sickness Severity and ithleteTM Heart Rate Variability Scores 
Figure 5 Receiver operating characteristic (ROC) Curve for Heart Rate Variability score for 
Detection of severe Acute Mountain Sickness  
Figure 6 Receiver operating characteristic (ROC) Curve for change in Heart Rate Variability 
score and identification of severe Acute Mountain Sickness 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Table 1: Baseline Demographics  
Demographic Result  
Number  21 
Age, years (range)  36..2±6.5 (26-48) 
Males n, % 20 (95.2%) 
Height, cm 177.3±7.9  
Weight, kg/m2 76.2±8.7 
Heart rate/ minute 59.7±12.0 
Systolic blood pressure  134.3±12.3 
Diastolic blood pressure 80.0±8.4 
Body mass index kg/m2 24.2±2.0 
Ethnicity, % 
- Caucasian  
 
100% 
Smoking status (N, %) 
- Current  
- Ex  
- Never 
 
9.5% 
33.3% 
57.2% 
 
Table 1
Table 1. Effect of High Altitude on Physiological measurements, Lake Louise Scores for 
Acute Mountain Sickness and Heart Rate Variability  
 1400m 890m 2650m 3700m 4100m 5140m P Value 
SpO2, % 96.6±1.4 96.9±1.7 94.3±2.2 88.8±3.4 88.0±3.4 79.3±5.7 <0.001bcd 
Heart rate, 
beats/min 
62.3±10.5 60.9±9.6 64.1±11.4 70.8±10.7 76.0±10.4 79.5±11.6 <0.001bcd 
LLS 
(range) 
0.4±0.7 
(0-2) 
0.3±0.7 
(0-2) 
2.2±5.5 
(0-23) 
1.3±2.1 
(0-9) 
1.1±2.5 
(0-16) 
1.8±2.9 
(0-15) 
 
0.04b 
HRV Score  79.6±14.5 82.8±13.0 78.7±13.1 74.3±14.6* 74.5±12.4* 76.0±12.5* 0.09 
LLS, Lake Louis Score for Acute Mountain Sickness; HRV Heart Rate Variability; * significant (p<0.05) 
differences in unpaired test vs 890m.; a 1400m vs 890m, b 2650m vs 890m, c 3700m vs 890m, d 4100m vs 890m, 
e 5140m vs 890m  
 
Table 2 
Figure 1 Click here to download Figure Fig 1 Clin J Sport Med Ascent profile.jpg 
Figure 2 Click here to download Figure Fig 2 Clin J Sport Med HRV and alt.jpg 
Figure 3 Click here to download Figure Fig 3 Clin J Sport Med AMS scores and HRV.jpg 
Figure 4 Click here to download Figure Fig 4 Clin J Sport Med Ams versus ams.jpg 
Figure 5 Click here to download Figure Fig 5 Clin J Sport Med ROC Curve HRV score.jpg 
Figure 6 Click here to download Figure Fig 6 Clin J Sport Meddeta HRV score.jpg 
